Search Login Register

Raloxifene (Evista) Summary

Description: A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Also Known As: Evista; ELi Lilly Brand of Raloxifene; Keoxifene; Keoxifene Hydrochloride; LY 139481 Show All >>

Networked: 1402 relevant articles (146 outcomes, 434 trials/studies) for this Drug

Key Diseases for which Raloxifene is Relevant

  1. Breast Neoplasms (Breast Cancer) : 56 outcomes 167 studies in 489 results
  2. Osteoporosis : 49 outcomes 152 studies in 555 results
  3. Postmenopausal Osteoporosis : 11 outcomes 19 studies in 158 results
  4. Neoplasms (Cancer) : 9 outcomes 23 studies in 113 results
  5. Schizophrenia (Dementia Praecox) : 6 outcomes 9 studies in 13 results
Show All >>

Drugs Related to Raloxifene

  1. Tamoxifen
  2. Selective Estrogen Receptor Modulators (SERM)
  3. Estrogens (Estrogen)
  4. Alendronate (Alendronate Sodium)
  5. Estradiol (Estrace)
  6. bazedoxifene acetate
  7. Raloxifene (Evista)
  8. risedronic acid (risedronate)
  9. Diphosphonates
  10. tartrate salt cis- 1R- (4'- pyrrolidinoethoxyphenyl)- 2S- phenyl- 6- hydroxy- 1,2,3,4- tetrahydronaphthalene (Lasofoxifene)
Show All >>

Therapies Related to Raloxifene

  1. Chemoprevention
  2. Hysterectomy
  3. Estrogen Replacement Therapy
  4. Drug Therapy (Chemotherapy)
  5. Oral Administration
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.